Cost of Goods Sold (Quarterly)

Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.

Xeris Biopharma Holdings, Inc. (XERS) had Cost of Goods Sold of $10.95M for the most recently reported fiscal quarter, ending 2025-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-12-31

Income Statement Financials
Revenue	$85.81M
Net Income	$11.08M
Cost of Goods Sold	$10.95M
Gross Profit	$74.86M
Operating Expenses	$69.03M
Operating Income	$16.77M
Non-Operating Income/Expense	$-5.69M
Pre-Tax Income	$11.08M
Normalized Pre-Tax Income	$11.08M
Income after Taxes	$11.08M
Income from Continuous Operations	$11.08M
Consolidated Net Income/Loss	$11.08M
Normalized Income after Taxes	$11.08M
EBIT	$16.77M
EBITDA	$20.84M
Weighted-Average Shares Outstanding (Basic)	160.43M
Weighted-Average Shares Outstanding (Diluted)	172.74M
Earnings per Share (EPS) (Basic)	$0.07
Earnings per Share (EPS) (Diluted)	$0.07
Balance Sheet Financials
Current Assets	$240.31M
Property, Plant, and Equipment	$4.95M
Long-Term Assets	$143.21M
Total Assets	$383.53M
Current Liabilities	$109.57M
Long-Term Debt	$220.34M
Long-Term Liabilities	$260.26M
Total Liabilities	$369.84M
Common Equity	$13.69M
Tangible Shareholders Equity	$-97.25M
Shareholders Equity	$13.69M
Common Shares Outstanding	166.22M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$28.63M
Cash Flow from Investing Activities	$-0.70M
Cash Flow from Financial Activities	$11.39M
Beginning Cash	$75.74M
End Cash	$115.06M
Increase/Decrease in Cash	$39.32M
Stock-Based Compensation	$22.37M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.19
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.94
Debt to Equity Ratio	16.10
Gross Margin	87.24%
Operating Margin	19.55%
EBIT Margin	19.55%
EBITDA Margin	--
Pre-Tax Profit Margin	12.91%
Profit Margin	12.91%
Free Cash Flow	$27.93M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.22
Inventory Turnover	0.16
Receiveable Turnover	1.68
Days Sales in Receivables	53.54
Return on Equity	80.95%
Return on Tangible Equity	-11.39%
Return on Assets	2.89%
Return on Investments	4.74%
Book Value Per Share	$0.08
Free Cash Flow per Share	$0.16
Operating Cash Flow per Share	$0.17

Data from Zacks Investment Research, Inc.